Gossamer Bio Announces Closing of Initial Public Offering & Full Exercise of Underwriters’ Option to Purchase Additional Sh...
February 12 2019 - 4:05PM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced the closing
of its previously announced initial public offering of 19,837,500
shares of its common stock, which includes the exercise in full by
the underwriters of their option to purchase 2,587,500 additional
shares, at a price to the public of $16.00 per share.
Including the option exercise, the aggregate gross proceeds
to Gossamer Bio from the offering, before deducting the
underwriting discounts and commissions and other offering expenses,
were $317.4 million. Gossamer Bio’s common stock is listed on
the Nasdaq Global Select Market under the ticker symbol “GOSS.”
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore
ISI acted as joint book-running managers for the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and
became effective on February 7, 2019. A prospectus relating to
and describing the terms of the offering has been filed with the
SEC and is available on the SEC's website at www.sec.gov.
The offering was made only by means of a prospectus. Copies of
the final prospectus related to this offering can be obtained from
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street,
3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email
at dg.prospectus_requests@baml.com; or from SVB Leerink,
Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@svbleerink.com;
or from Barclays, c/o Broadridge Financial Solutions, Attn:
Prospectus Department, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (888) 603-5847, or by email
at barclaysprospectus@broadridge.com; or from Evercore ISI,
Attention: Equity Capital Markets, 55 East 52nd Street,
36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190212005898/en/
Gossamer Bio:For Investors:Argot PartnersKimberly
MinarovichTel 212.600.1902kimberly@argotpartners.comFor
Media:Argot PartnersDavid
RosenTel 212.600.1902david.rosen@argotpartners.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Jul 2023 to Jul 2024